DNMT3A and diabetic kidney disease: Although it remains to be further explored whether ERK/MEK signalling regulates the subcellular translocation of Dnmt3a post-transcriptionally or through protein-protein interactions, our study clearly reveals a novel regulatory mechanism of CTGF expression in diabetic nephropathy and strongly supports the therapeutic value of ERK/MAPK inhibitors in the prevention and treatment of diabetic nephropathy.